## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 2054	49

<b>STATEMENT</b>	OF CHAI	NGES IN	BENEFICIAL	<b>OWNERSHIP</b>
0 17 (1 E.IVIE14 1	O. O		DE:112: 10:7 12	O 1111E1101111

OMB APPI	ROVAL								
OMB Number: 3235-									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Enyedy (Last) C/O IMM	1. Name and Address of Reporting Person*  Enyedy Mark J  (Last) (First) (Middle)  C/O IMMUNOGEN, INC.  830 WINTER STREET					Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [ IMGN ]      Inc. [ IMGN ]      Indicate the second of the second						Office (city title			ner	
(Street) WALTH	AM N	IA state)	02451 (Zip)		If Amendment, Date of Original Filed (Month/Day/Year)      Ative Securities Acquired, Disposed of, or Benefic					Line)	Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3)  2. Trans: Date		Transact	action 2A. Deemed Execution Date,		3. Transaction	4. Securi	ecurities Acquired (A) oposed Of (D) (Instr. 3, 4		5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of ndirect Beneficial Dwnership Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code	ransaction Derivative Exp ode (Instr. Securities (Mo		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	)ii(3)		
Stock Option (Right to Buy)	\$4.55	05/20/2022		A		393,750		05/20/2022 <sup>(1)</sup>	02/07/2030	Common Stock	393,750	\$0	393,750	0	D	
Stock Option (Right to Buy)	\$4.55	11/14/2022		A		787,500		11/14/2022 <sup>(2)</sup>	02/07/2030	Common Stock	787,500	\$0	1,181,25	50	D	

## **Explanation of Responses:**

1. On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.

2. On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.

/s/ Renee Lentini, Attorney-in-

Fact

\*\* Signature of Reporting Person

12/27/2022 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.